Breaking Finance News

iKang Healthcare Group Inc (ADR) (NASDAQ:KANG) has been downgraded to Sell in a statement by TheStreet earlier today.

TheStreet has downgraded iKang Healthcare Group Inc (ADR)(NASDAQ:KANG) to Sell in a report released on 8/17/2016.

Yesterday iKang Healthcare Group Inc (ADR) (NASDAQ:KANG) traded 0.60% lower at $18.95. iKang Healthcare Group Inc (ADR)’s 50-day moving average is $18.55 and its two hundred day average is $19.67. The last stock price close is down 8.10% relative to the 200-day average, compared to the S&P 500 Index which has decreased -0.01% over the same time period. 83,946 shares of iKang Healthcare Group Inc (ADR) traded hands, down from ann avg. volume of 208,406.

See Chart Below:

iKang Healthcare Group Inc (ADR) (NASDAQ:KANG)

iKang Healthcare Group Inc (ADR) has a one-year low of $14.20 and a one-year high of $22.58 with a price-earnings ratio of 125 and has a market cap of $0.0.

Brief Synopsis About iKang Healthcare Group Inc (ADR) (NASDAQ:KANG)

iKang Healthcare Group, Inc. provides preventive healthcare solutions, including a range of medical examinations services and value-added services, including disease screening, dental services and other services in China. The Company’s segments include medical examinations and other medical services, and dental services. The Company, through its integrated service platform, offers healthcare management solutions, including medical examinations, which cover basic examination items, such as internal, gynecology, ophthalmology, dental and X-ray, and value-added services at selected medical centers, including disease screening focusing on cancer screening, cardiovascular disease screening, certain chronic disease screening and functional medicine testing; dental care, including oral health, pediatric dentistry and cosmetic dentistry; outpatient services, such as acupuncture, obstetrics, gynecology and minor surgery, and and on-site healthcare management or clinics at certain locations.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with's FREE daily email newsletter.